MX2010004813A - Factor viii recombinante que tiene estabilidad incrementada. - Google Patents
Factor viii recombinante que tiene estabilidad incrementada.Info
- Publication number
- MX2010004813A MX2010004813A MX2010004813A MX2010004813A MX2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A MX 2010004813 A MX2010004813 A MX 2010004813A
- Authority
- MX
- Mexico
- Prior art keywords
- factor viii
- recombinant factor
- increased stability
- nucleic acid
- acid molecule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
La presente invención se refiere a un factor VIII recombinante que incluye una o más mutaciones que resultan en estabilidad mejorada tanto del factor VIII como factor VIIIa. Los métodos para hacer y usar el factor VIII recombinante, y composiciones farmacéuticas que contienen el mismo también se describen. La presente invención adicionalmente se refiere a una molécula de ácido nucleico aislada que codifica el factor VIII recombinante, así como también sistemas de expresión de ADN y células huésped que contienen la molécula de ácido nucleico aislada.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98451807P | 2007-11-01 | 2007-11-01 | |
US99130407P | 2007-11-30 | 2007-11-30 | |
PCT/US2008/071170 WO2009058446A1 (en) | 2007-11-01 | 2008-07-25 | Recombinant factor viii having increased stability |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010004813A true MX2010004813A (es) | 2010-10-04 |
Family
ID=40588749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004813A MX2010004813A (es) | 2007-11-01 | 2008-07-25 | Factor viii recombinante que tiene estabilidad incrementada. |
Country Status (13)
Country | Link |
---|---|
US (4) | US8338571B2 (es) |
EP (2) | EP2711436A1 (es) |
JP (2) | JP2011502478A (es) |
KR (1) | KR20100113478A (es) |
CN (2) | CN101965409A (es) |
AU (1) | AU2008319183B2 (es) |
BR (1) | BRPI0818913A2 (es) |
CA (1) | CA2703948A1 (es) |
IL (1) | IL205422A0 (es) |
MX (1) | MX2010004813A (es) |
RU (2) | RU2531493C2 (es) |
WO (1) | WO2009058446A1 (es) |
ZA (1) | ZA201003049B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120028900A1 (en) * | 2006-06-30 | 2012-02-02 | Kaufman Randal J | Method of producing factor viii proteins by recombinant methods |
US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
AU2007269233B2 (en) * | 2006-06-30 | 2011-06-09 | Cnj Holdings, Inc. | Method of producing Factor VIII proteins by recombinant methods |
AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
EP2536752B1 (en) * | 2010-02-16 | 2015-04-08 | Novo Nordisk A/S | Modified recombinant Factor VIII |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8637448B2 (en) | 2010-09-14 | 2014-01-28 | University Of Rochester | Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
DE102010042458A1 (de) * | 2010-10-14 | 2012-04-19 | Siemens Aktiengesellschaft | Verfahren zum Betreiben einer kombinierten Gas- und Dampfturbinenanlage sowie zur Durchführung des Verfahrens hergerichtete Gas- und Dampfturbinenanlage und entsprechende Regelvorrichtung |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
BR112014017165B1 (pt) * | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos |
EP3549953A1 (en) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP2666782A1 (en) | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
CN110054699A (zh) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP6523244B2 (ja) * | 2013-03-15 | 2019-05-29 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 変異体第viii因子ポリペプチドならびにそれらの製造方法および使用方法 |
WO2015023894A1 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
EP3060242A1 (en) * | 2013-10-22 | 2016-08-31 | DBV Technologies | Method of treating haemophilia by inducing tolerance to blood factors |
CN103613658B (zh) * | 2013-11-15 | 2015-04-01 | 同路生物制药股份有限公司 | 一种人第viii凝血因子的制备方法 |
GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
CN106456718A (zh) | 2014-01-10 | 2017-02-22 | 比奥根Ma公司 | 因子viii嵌合蛋白及其用途 |
EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
WO2017011275A1 (en) | 2015-07-10 | 2017-01-19 | Nersissian Aram M | Factor viii protein compositions and methods of treating hemophilia a |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
MA42934A (fr) | 2015-09-24 | 2018-08-01 | Biomarin Pharm Inc | Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci |
AU2019366942A1 (en) * | 2018-10-23 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor VIII function |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US6376463B1 (en) * | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US5576291A (en) * | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
US5880327A (en) * | 1994-09-21 | 1999-03-09 | American National Red Cross | Transgenic mammals expressing human coagulation factor VIII |
US8183344B2 (en) * | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
US5804420A (en) * | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
US5994310A (en) | 1998-09-03 | 1999-11-30 | Bayer Corporation | Peptide ligands for affinity purification of human Factor VIII |
US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
EP1038959A1 (en) | 1999-03-17 | 2000-09-27 | Aventis Behring Gesellschaft mit beschränkter Haftung | Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX |
WO2001003726A1 (en) * | 1999-07-13 | 2001-01-18 | Biovitrum Ab | Stable factor viii compositions |
US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
JP2004525608A (ja) | 2000-09-19 | 2004-08-26 | エモリー ユニバーシテイ | 修飾された因子viii |
EP1233064A1 (en) | 2001-02-09 | 2002-08-21 | Aventis Behring Gesellschaft mit beschränkter Haftung | Modified factor VIII cDNA and its use for the production of factor VIII |
ES2331909T3 (es) * | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
EP1424344A1 (en) | 2002-11-29 | 2004-06-02 | Aventis Behring Gesellschaft mit beschränkter Haftung | Modified cDNA factor VIII and its derivates |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
WO2005055930A2 (en) * | 2003-12-03 | 2005-06-23 | University Of Rochester | Recombinant factor viii having increased specific activity |
SG173326A1 (en) * | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
-
2008
- 2008-07-25 BR BRPI0818913 patent/BRPI0818913A2/pt not_active IP Right Cessation
- 2008-07-25 WO PCT/US2008/071170 patent/WO2009058446A1/en active Application Filing
- 2008-07-25 JP JP2010532092A patent/JP2011502478A/ja active Pending
- 2008-07-25 RU RU2010122052/10A patent/RU2531493C2/ru not_active IP Right Cessation
- 2008-07-25 CA CA2703948A patent/CA2703948A1/en not_active Abandoned
- 2008-07-25 AU AU2008319183A patent/AU2008319183B2/en not_active Ceased
- 2008-07-25 EP EP13192168.6A patent/EP2711436A1/en not_active Withdrawn
- 2008-07-25 CN CN2008801237515A patent/CN101965409A/zh active Pending
- 2008-07-25 US US12/179,801 patent/US8338571B2/en not_active Expired - Fee Related
- 2008-07-25 CN CN201410171441.8A patent/CN104152489A/zh active Pending
- 2008-07-25 US US12/179,951 patent/US8183345B2/en not_active Expired - Fee Related
- 2008-07-25 KR KR1020107011039A patent/KR20100113478A/ko not_active Application Discontinuation
- 2008-07-25 EP EP08782378.7A patent/EP2209908B1/en not_active Not-in-force
- 2008-07-25 MX MX2010004813A patent/MX2010004813A/es active IP Right Grant
-
2010
- 2010-04-29 IL IL205422A patent/IL205422A0/en unknown
- 2010-04-30 ZA ZA2010/03049A patent/ZA201003049B/en unknown
-
2012
- 2012-11-30 US US13/691,474 patent/US9072722B2/en not_active Expired - Fee Related
-
2013
- 2013-10-11 US US14/052,452 patent/US20140056861A1/en not_active Abandoned
-
2014
- 2014-07-18 RU RU2014129759A patent/RU2014129759A/ru not_active Application Discontinuation
- 2014-12-26 JP JP2014264026A patent/JP2015110589A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2008319183B2 (en) | 2014-09-04 |
EP2209908A1 (en) | 2010-07-28 |
US20130085110A1 (en) | 2013-04-04 |
EP2209908B1 (en) | 2014-09-03 |
RU2010122052A (ru) | 2011-12-10 |
CN101965409A (zh) | 2011-02-02 |
IL205422A0 (en) | 2010-12-30 |
ZA201003049B (en) | 2012-11-28 |
EP2209908A4 (en) | 2011-06-01 |
US8338571B2 (en) | 2012-12-25 |
CA2703948A1 (en) | 2009-05-07 |
BRPI0818913A2 (pt) | 2015-05-12 |
US20090118185A1 (en) | 2009-05-07 |
AU2008319183A1 (en) | 2009-05-07 |
CN104152489A (zh) | 2014-11-19 |
JP2015110589A (ja) | 2015-06-18 |
RU2014129759A (ru) | 2016-02-10 |
RU2531493C2 (ru) | 2014-10-20 |
US8183345B2 (en) | 2012-05-22 |
US20140056861A1 (en) | 2014-02-27 |
KR20100113478A (ko) | 2010-10-21 |
US9072722B2 (en) | 2015-07-07 |
WO2009058446A1 (en) | 2009-05-07 |
US20090118184A1 (en) | 2009-05-07 |
EP2711436A1 (en) | 2014-03-26 |
JP2011502478A (ja) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004813A (es) | Factor viii recombinante que tiene estabilidad incrementada. | |
MX2009002816A (es) | Proteinas de fusion de albumina. | |
WO2011106766A3 (en) | Modified proteins and methods of making and using same | |
CY1117401T1 (el) | Πρωτεϊνες συντηξης αλβουμινης | |
TNSN08064A1 (en) | Albumin fusion proteins | |
DK1928901T3 (da) | Polypeptider, der har beta-glucosidaseaktivitet og polynukleotider, der koder for samme | |
ATE483027T1 (de) | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen | |
IN2012DN00403A (es) | ||
WO2011028344A3 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
MY177065A (en) | 4-1bb binding molecules | |
MX2007007862A (es) | Proteasas fungales acidas. | |
WO2007146038A3 (en) | Albumin fusion proteins | |
WO2005056759A3 (en) | Methods of generating variant proteins with increased host string content and compositions thereof | |
MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
MX2009012846A (es) | Polipeptidos que tienen actividad celulosica mejorada y polinucleotidos que los codifican. | |
TW200740841A (en) | Polypeptides having antimicrobial activity and polynucleotides encoding same | |
CY1114483T1 (el) | Νεα ρυθμιστικα στοιχεια | |
MX2010004674A (es) | Variantes de alfa-amilasa con propiedades alteradas. | |
MX2010001490A (es) | Acidos nucleicos de enlace sdf-1 y uso de los mismos. | |
WO2007136835A3 (en) | Methods and cells for creating functional diversity and uses thereof | |
MX2017009153A (es) | Proteinas de fusion de citoquinas. | |
WO2010147462A9 (en) | Novel stringent selectable markers | |
WO2013013017A3 (en) | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics | |
IN2015DN03206A (es) | ||
WO2009010251A3 (en) | Mutant dna polymerases and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |